Tildacerfont |
| Catalog No.GC65893 |
Tildacerfont est un antagoniste puissant et actif par voie orale du récepteur du facteur de libération de la corticotrophine de type 1 (CRF1). Tildacerfont réduit efficacement les taux d'hormone corticotrope (ACTH) et d'androgènes surrénaliens. Tildacerfont a un profil de sécurité favorable. Tildacerfont peut être utilisé pour rechercher l'hyperplasie congénitale des surrénales.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1014983-00-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia[1].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *